Wide Ranks

EQ

Equillium, Inc.

0.7700

Top Statistics
Market Cap 27 M Forward PE -0.7219 Revenue Growth 51.80 %
Current Ratio 2.08 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -19.51 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.8820 Enterprise / Revenue -0.1980 Price To Sales Trailing12 Months 0.6401
Profitability
Profit Margins -19.51 % Operating Margins -0.72 %
Balance Sheet
Total Cash 33 M Total Cash Per Share 0.9400 Total Debt 609000
Total Debt To Equity 2.71 Current Ratio 2.08 Book Value Per Share 0.6400
All Measures
Short Ratio 53.00 % Message Board Id finmb_575585027 Shares Short Prior Month 190494
Return On Equity -0.3367 City La Jolla Uuid 2dcbad74-77fd-3056-9e8b-8198f173bd47
Previous Close 0.7799 First Trade Date Epoch Utc 1 B Book Value 0.6400
Beta 1.83 Total Debt 609000 Volume 47236
Price To Book 1.20 Fifty Two Week Low 0.4800 Total Cash Per Share 0.9400
Total Revenue 42 M Shares Short Previous Month Date 1 B Target Median Price 3.00
Max Age 86400 Recommendation Mean 1.75 Sand P52 Week Change 0.3133
Operating Margins -0.72 % Target Mean Price 3.33 Net Income To Common -8318000
Short Percent Of Float 0.0054 Implied Shares Outstanding 35 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 111170 Average Volume10days 111170
Total Cash 33 M Next Fiscal Year End 1 B Revenue Per Share 1.21
Held Percent Insiders 0.3621 Ebitda Margins -22.49 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.7799
Target Low Price 2.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.8892
Open 0.7826 Free Cashflow -6715875 State CA
Dividend Yield 0.00 % Return On Assets -0.1195 Time Zone Short Name EST
Trailing Eps -0.1200 Day Low 0.7410 Address1 2223 Avenida De La Playa
Shares Outstanding 35 M Price Hint 4 Target High Price 5.00
Website https://www.equilliumbio.com 52 Week Change 0.3276 Average Volume 181370
Forward Eps -1.28 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 199.80 % Is_sp_500 False Regular Market Day High 0.8299
Profit Margins -19.51 % Debt To Equity 2.71 Fifty Two Week High 3.25
Day High 0.8299 Shares Short 117561 Regular Market Open 0.7826
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -0.1980
Revenue Growth 51.80 % Shares Percent Shares Out 0.0033 Operating Cashflow -15643000
Currency USD Time Zone Full Name America/New_York Market Cap 27 M
Is_nasdaq_100 False Zip 92037 Quote Type EQUITY
Industry Biotechnology Long Name Equillium, Inc. Regular Market Day Low 0.7410
Held Percent Institutions 0.2004 Current Price 0.7700 Address2 Suite 105
Enterprise To Ebitda 0.8820 Financial Currency USD Current Ratio 2.08
Gross Margins 100.00 % Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 17 M Two Hundred Day Average 1.29
Enterprise Value -8452634 Price To Sales Trailing12 Months 0.6401 Forward PE -0.7219
Regular Market Volume 47236 Ebitda -9584000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.

The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.

In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area.

Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy.

The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.

Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.